A Preclinical Research Scientist plays a crucial role in the transition from basic laboratory findings to clinical application. Their primary focus is evaluating the safety, efficacy, and biological behavior of drug candidates before they are tested in humans. This involves conducting a wide range of in vitro (cell-based) and in vivo (animal-based) experiments to understand how a compound interacts with the body and how the body processes it. Key areas of investigation include toxicity, pharmacokinetics (absorption, distribution, metabolism, and excretion), and pharmacodynamics (how the drug affects biological systems). These studies provide essential data for determining appropriate dosage levels and identifying potential risks.
Working at the interface of discovery and clinical development, Preclinical Research Scientists collaborate with toxicologists, pathologists, regulatory experts, and data scientists to design comprehensive study protocols. They generate detailed reports and interpret complex biological responses to assess whether a compound has a favorable safety margin for human testing. Regulatory guidelines, such as those from the FDA or EMA, shape much of their work to ensure that studies meet the rigorous standards required for Investigational New Drug (IND) applications. Advances in cell modeling, organ-on-chip technology, and predictive analytics are expanding the tools available for this critical stage. Their efforts are foundational in minimizing risk and ensuring that only the most promising and safe drug candidates move forward into clinical trials.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia